Clal Biotechnology reported ILS158.39M in Assets for its fiscal quarter ending in December of 2023.





Assets Change Date
Arca Biopharma USD 504.48M 15.86M Mar/2026
aTyr Pharma USD 79.65M 435.68M Mar/2026
Bio Path USD 690K 56K Sep/2025
Brainstorm Cell Therapeutics USD 755K 267K Mar/2026
Cara Therapeutics USD 32.07M 6.95M Dec/2025
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 156.57M 58.73M Dec/2025
Immunic USD 189.74M 165.69M Mar/2026
Infinity Pharmaceuticals USD 21.23M 8.72M Jun/2023
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
RedHill Biopharma USD 18.38M 332K Jun/2025
TherapeuticsMD USD 40.13M 1.96M Jun/2024